

- Critical care medicine, essentials in (*Continued*)
 shock in, 263
 systemic inflammatory response syndrome in, 263
- Critical illness myopathy (CIM), 1097
- Critical illness polyneuropathy (CIP), 1085
- Crizotinib, 590t
- Crohn's disease, 418. *see also* Inflammatory bowel disease (IBD).
 clinical presentation of, 419
 definition of, 417-418
 diagnosis and differential diagnosis of, 420-421, 421f-422f
 differentiating features of ulcerative colitis and, 420t
 epidemiology of, 417-418
 extraintestinal manifestations of, 419-420, 419t
 prognosis of, 424
 spondyloarthropathy and, 777
 surgical management of, 424
 treatment of, 421-424, 422t
- Crossover, chromosomal, 8, 9f
- Croup, in common cold, 867
- Cryoglobulinemia, 322, 323t
- Cryoglobulinemic glomerulonephritis, 322-323, 323t
- Cryoprecipitate, 562, 562.e1f
- Cryptococcal meningitis
 clinical presentation of, 855
 in HIV-infected patients, 940
- Cryptococcus neoformans* infection, meningitis in, 854
- Cryptogenic fibrosing alveolitis, 224-226
- Cryptogenic organizing pneumonia (COP), 224
- Cryptorchidism, 653
 testicular cancer and, 724
- Cryptosporidium*, 900t, 954t
- Cryptosporidium parvum*, in HIV-infected patients, 938, 938t
- Crystal-induced arthropathies, 801
- Crystal nephropathy, in intrinsic acute kidney injury, 359
- Crystals, in urine, 295f
- CSF. *see* Cerebrospinal fluid (CSF).
- CT. *see* Computed tomography (CT).
- CTA. *see* Computed tomographic angiography (CTA).
- Culture, 832-833, 833t
- Culture-negative endocarditis (CNE), 878
 diagnostic approach to, 880t
 infectious, 878-880
- CURB-65 score, for pneumonia, 875
- Cushing's disease, 630-631, 630f, 646, 649
- Cushing's syndrome, 646-649
 causes of, 646, 647t
 clinical presentation of, 646-647, 647t
 diagnosis of, 647-649, 648f
 differential diagnosis of, 649
 hypertension secondary to, 170t
 in lung cancer, 646
 pathophysiology of, 646
 subclinical, 651
 treatment of, 649
- Cyanide poisoning, 264
- Cyanosis, 26
 central, 187
- Cyanotic heart disease, 73-75
- Cyclic adenosine monophosphate (cAMP), 58
- Cyclo-oxygenase-1 (COX-1), 405-406, 406f
- Cyclo-oxygenase-2 (COX-2), 405-406, 406f
 for osteoarthritis, 807
 selective, in acute kidney injury, 356
- Cyclo-oxygenase-2 (COX-2) inhibitors
 adverse cardiovascular effects of, 405-406
 gastric mucosa and, 405-406
 platelet function and, 554
- Cyclobenzaprine, for fibromyalgia syndrome, 812
- Cyclophosphamide, 587t
 for aplastic anemia, 483
 bone health and, 785
 in premature ovarian failure, 797-798
 for systemic lupus erythematosus, 784
 for systemic sclerosis, 791
 for vasculitides, ANCA-associated, 796
- Cyclospora*, 900t
- Cyclosporine, 369-370
 for aplastic anemia, 483
 for inflammatory bowel disease, 423
- Cystic fibrosis, 208t, 217-218
- Cystic kidney diseases, 332-333
 acquired, 335-336
- Cysticercosis, 956-957
- Cystine stones, 340
- Cystinuria, 340
- Cysts, in kidney, 333
- Cytokines, 823, 824t
 as anticancer agents, 590
 as endogenous pyrogens, 835
 hematopoiesis and, 478-479, 479t
 in rheumatoid arthritis, 771
 skin and soft tissue infections and, 884
- Cytomegalovirus (CMV)
 infection
 esophagitis, 401
 fever in, 843-844
 mononucleosis syndrome in, 837, 843-844
 Ménétrier disease caused by, 413
 retinitis, in HIV-infected patients, 931
- Cytoreductive nephrectomy, for metastatic renal cell carcinoma, 605
- Cytotoxic T-lymphocyte antigen 4 (CTLA-4), for melanoma, 616
- D**
- D-dimer, 542
 in disseminated intravascular coagulation, 553
- D-dimer test
 in deep vein thrombosis, 165
 in pulmonary embolism, 166, 243
 recurrence risk for thromboembolism and, 571-572
- D-xylose test, 382
- Dabrafenib, for melanoma, 616
- Dactylitis, 776
 in sickle cell disease, 815
- Dasatinib, 494, 590t
- Dawn phenomenon, 662
- DDAVP. *see* Desmopressin (DDAVP).
- de Quervain's thyroiditis, 637
- Dead space, anatomic, 190-191
- Dead space ratio, 192, 192f
- Deafness, acute unilateral, 1009
- 1-deamino-(8-D-arginine)-vasopressin (DDAVP)
 for bleeding
 caused by aspirin, 555
 in uremic platelet dysfunction, 556
 for von Willebrand disease, 558
- Decerebrate posturing, 967
- Decitabine, for myelodysplastic syndrome, 487
- Declarative memory, 983-984
- Decorticate posturing, 967
- Deep vein thrombosis, 165. *see also* Venous thromboembolism.
- Defibrillation, 115
- Defibrotide, for veno-occlusive disease, 467-468
- Delayed afterdepolarizations (DADs), 111
- Delirium, 965, 1108, 1108t
 hyperactive terminal, 1122-1123
 palliative care and, 1120
- Delirium tremens, 1128
 medical management of, 1132
- Delta waves, 121-122
- Delusional disorder, 989
- Dementia, 980-984, 1108
 acquired immunodeficiency syndrome and, 983
 causes of, 980t
 from chronic meningitis, 983
 cortical vs. subcortical, 980t
 in Creutzfeldt-Jakob disease, 866, 983
 delirium vs., 1108t
 diffuse Lewy body disease and, 982
 etiologic diagnosis of, 980t
 frontotemporal, 983
 in HIV-infected patients, 939
 with Lewy bodies, 1018
 major syndromes of, 980-983
 Montreal Cognitive Assessment for, 980-981, 981t
 in normal-pressure hydrocephalus, 983
 palliative care and, 1116-1117
 Parkinson's disease and, 983
 from prion infection, 983
- Demyelinating disorders, 1005, 1069-1076
 neuromyelitis optica, 1005
 optic neuritis, 1005
- Dendritic cells, 825
 immature, 829
 in kidney, 284
- Denosumab, 763
 for osteoporosis prevention and treatment, 762t
- Dense deposit disease, 319-320
- Dentatorubropallidolusian atrophy (DRPLA), 1020
- Deposition disease, 358
- Depot medroxyprogesterone acetate (DMPA), 701
- Depression
 chronic abdominal pain in, 373
 dementia and, 984
 in epilepsy, 1051
 in fibromyalgia syndrome, 809
 in older adults, 1107t
 in palliative care, 1120
 screening of women for, 702t
- Depressive disorders, 985-987
 psychotherapies and antidepressant medications for, 987t
- Dermatologic toxicity, 621